Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker LBRX
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Oct 13, 2026 | SCHEDULE 13G/A (amended) | LBRX LB Pharmaceuticals Inc | JPMorgan Chase & Co. | 1.40M | 4.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | LBRX LB Pharmaceuticals Inc | Chen Yu | 1.45M | 5.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | LBRX LB Pharmaceuticals Inc | TCG Crossover Fund II, L.P. | 1.45M | 5.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | LBRX LB Pharmaceuticals Inc | TCG Crossover GP II, LLC | 1.45M | 5.0% | SCHEDULE 13G/A ↗ |
| Jul 29, 2026 | SCHEDULE 13G/A (amended) | LBRX LB Pharmaceuticals Inc | BlackRock, Inc. | 1.80M | 6.3% | SCHEDULE 13G/A ↗ |
| Jul 16, 2026 | SCHEDULE 13G | LBRX LB Pharmaceuticals Inc | JPMorgan Chase & Co | 1.50M | 5.2% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | LBRX LB Pharmaceuticals Inc | Michael Kramarz | 1.97M | 6.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | LBRX LB Pharmaceuticals Inc | Robert Egen Atkinson | 1.97M | 6.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | LBRX LB Pharmaceuticals Inc | Commodore Capital Master LP | 1.97M | 6.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | LBRX LB Pharmaceuticals Inc | Commodore Capital LP | 1.97M | 6.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G | LBRX LB Pharmaceuticals Inc | David Edward Johnson | 1.44M | 5.0% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | LBRX LB Pharmaceuticals Inc | Caligan Partners LP | 1.44M | 5.0% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | LBRX LB Pharmaceuticals Inc | Chen Yu | 1.84M | 6.4% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | LBRX LB Pharmaceuticals Inc | TCG Crossover Fund II, L.P. | 1.84M | 6.4% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | LBRX LB Pharmaceuticals Inc | TCG Crossover GP II, LLC | 1.84M | 6.4% | SCHEDULE 13G/A ↗ |
| May 13, 2026 | SCHEDULE 13G/A (amended) | LBRX LB Pharmaceuticals Inc | JPMorgan Chase & Co | 1.43M | 4.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | LBRX LB Pharmaceuticals Inc | RA Capital Healthcare Fund, L.P. | 2.21M | 8.7% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | LBRX LB Pharmaceuticals Inc | Rajeev Shah | 2.21M | 8.7% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | LBRX LB Pharmaceuticals Inc | Peter Kolchinsky | 2.21M | 8.7% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | LBRX LB Pharmaceuticals Inc | RA Capital Management, L.P. | 2.21M | 8.7% | SCHEDULE 13G/A ↗ |
| Feb 10, 2026 | SCHEDULE 13D/A (amended) | LBRX LB Pharmaceuticals Inc | David Kroin | 3.35M | 11.7% | SCHEDULE 13D/A ↗ |
| Feb 10, 2026 | SCHEDULE 13D/A (amended) | LBRX LB Pharmaceuticals Inc | Deep Track Capital, LP | 3.35M | 11.7% | SCHEDULE 13D/A ↗ |
| Feb 10, 2026 | SCHEDULE 13D/A (amended) | LBRX LB Pharmaceuticals Inc | Deep Track Special Opportunities Fund, LP | 666,666 | 2.3% | SCHEDULE 13D/A ↗ |
| Feb 10, 2026 | SCHEDULE 13D/A (amended) | LBRX LB Pharmaceuticals Inc | Deep Track Biotechnology Master Fund, Ltd. | 2.69M | 9.4% | SCHEDULE 13D/A ↗ |
| Jan 21, 2026 | SCHEDULE 13G/A (amended) | LBRX LB Pharmaceuticals Inc | BlackRock Portfolio Management LLC | 961,158 | 3.8% | SCHEDULE 13G/A ↗ |
| Jan 21, 2026 | SCHEDULE 13G | LBRX LB Pharmaceuticals Inc | BlackRock, Inc. | 1.28M | 5.1% | SCHEDULE 13G ↗ |
| Jan 21, 2026 | SCHEDULE 13G | LBRX LB Pharmaceuticals Inc | JPMorgan Chase & Co. | 1.61M | 6.3% | SCHEDULE 13G ↗ |
| Dec 31, 2025 | SCHEDULE 13G | LBRX LB Pharmaceuticals Inc | Ortav Yehudai | 1.27M | 5.0% | SCHEDULE 13G ↗ |
| Dec 31, 2025 | SCHEDULE 13G | LBRX LB Pharmaceuticals Inc | Trails Edge Biotechnology Master Fund, LP | 1.27M | 5.0% | SCHEDULE 13G ↗ |
| Dec 31, 2025 | SCHEDULE 13G | LBRX LB Pharmaceuticals Inc | Trails Edge Capital Partners, LP | 1.27M | 5.0% | SCHEDULE 13G ↗ |
| Oct 17, 2025 | SCHEDULE 13G | LBRX LB Pharmaceuticals Inc | BlackRock Portfolio Management LLC | 975,000 | 5.9% | SCHEDULE 13G ↗ |
| Sep 25, 2025 | SCHEDULE 13D | LBRX LB Pharmaceuticals Inc | Tomer Kariv | 1.41M | 6.3% | SCHEDULE 13D ↗ |
| Sep 25, 2025 | SCHEDULE 13D | LBRX LB Pharmaceuticals Inc | Ran Nussbaum | 1.41M | 6.3% | SCHEDULE 13D ↗ |
| Sep 25, 2025 | SCHEDULE 13D | LBRX LB Pharmaceuticals Inc | Pontifax VI G.P. L.P. | 1.41M | 6.3% | SCHEDULE 13D ↗ |
| Sep 25, 2025 | SCHEDULE 13D | LBRX LB Pharmaceuticals Inc | Pontifax Management 4 G.P. (2015) Ltd. | 1.41M | 6.3% | SCHEDULE 13D ↗ |
| Sep 19, 2025 | SCHEDULE 13G | LBRX LB Pharmaceuticals Inc | RA Capital Healthcare Fund, L.P. | 1.68M | 7.5% | SCHEDULE 13G ↗ |
| Sep 19, 2025 | SCHEDULE 13G | LBRX LB Pharmaceuticals Inc | Rajeev Shah | 1.68M | 7.5% | SCHEDULE 13G ↗ |
| Sep 19, 2025 | SCHEDULE 13G | LBRX LB Pharmaceuticals Inc | Peter Kolchinsky | 1.68M | 7.5% | SCHEDULE 13G ↗ |
| Sep 19, 2025 | SCHEDULE 13G | LBRX LB Pharmaceuticals Inc | RA Capital Management, L.P. | 1.68M | 7.5% | SCHEDULE 13G ↗ |
| Sep 19, 2025 | SCHEDULE 13D | LBRX LB Pharmaceuticals Inc | David Kroin | 3.35M | 14.9% | SCHEDULE 13D ↗ |
| Sep 19, 2025 | SCHEDULE 13D | LBRX LB Pharmaceuticals Inc | Deep Track Capital, LP | 3.35M | 14.9% | SCHEDULE 13D ↗ |
| Sep 19, 2025 | SCHEDULE 13D | LBRX LB Pharmaceuticals Inc | Deep Track Special Opportunities Fund, LP | 666,666 | 3.0% | SCHEDULE 13D ↗ |
| Sep 19, 2025 | SCHEDULE 13D | LBRX LB Pharmaceuticals Inc | Deep Track Biotechnology Master Fund, Ltd. | 2.69M | 12.0% | SCHEDULE 13D ↗ |
| Sep 18, 2025 | SCHEDULE 13G | LBRX LB Pharmaceuticals Inc | Michael Kramarz | 1.23M | 5.5% | SCHEDULE 13G ↗ |
| Sep 18, 2025 | SCHEDULE 13G | LBRX LB Pharmaceuticals Inc | Robert Egen Atkinson | 1.23M | 5.5% | SCHEDULE 13G ↗ |
| Sep 18, 2025 | SCHEDULE 13G | LBRX LB Pharmaceuticals Inc | Commodore Capital Master LP | 1.23M | 5.5% | SCHEDULE 13G ↗ |
| Sep 18, 2025 | SCHEDULE 13G | LBRX LB Pharmaceuticals Inc | Commodore Capital LP | 1.23M | 5.5% | SCHEDULE 13G ↗ |
| Sep 18, 2025 | SCHEDULE 13G | LBRX LB Pharmaceuticals Inc | Chen Yu | 1.75M | 7.8% | SCHEDULE 13G ↗ |
| Sep 18, 2025 | SCHEDULE 13G | LBRX LB Pharmaceuticals Inc | TCG Crossover Fund II, L.P. | 1.75M | 7.8% | SCHEDULE 13G ↗ |
| Sep 18, 2025 | SCHEDULE 13G | LBRX LB Pharmaceuticals Inc | TCG Crossover GP II, LLC | 1.75M | 7.8% | SCHEDULE 13G ↗ |
50 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:42 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances